Effectiveness of MRNA Vaccine Boosters Against Infection with the SARS-CoV-2 Omicron (B.1.1.529) Variant in Spain: a Nationwide Cohort Study

Overview

Journal Lancet Infect Dis

Specialty Infectious Diseases

Date 2022 Jun 6

PMID 35658998

Authors

Susana Monge

Ayelen Rojas-Benedicto

Carmen Olmedo

Clara Mazagatos

Maria Jose Sierra

Aurora Limia

Elisa Martin-Merino

Amparo Larrauri

Miguel A Hernan

Affiliations

Soon will be listed here.

Abstract

Background: The omicron (B.1.1.529) variant of SARS-CoV-2 has increased capacity to elude immunity and cause breakthrough infections. The aim of this study was to estimate the effectiveness of mRNA-based vaccine boosters (third dose) against infection with the omicron variant by age, sex, time since complete vaccination, type of primary vaccine, and type of booster.

Methods: In this nationwide cohort study, we linked data from three nationwide population registries in Spain (Vaccination Registry, Laboratory Results Registry, and National Health System registry) to select community-dwelling individuals aged 40 years or older, who completed their primary vaccine schedule at least 3 months before the start of follow-up, and had not tested positive for SARS-CoV-2 since the start of the pandemic. On each day between Jan 3, and Feb 6, 2022, we matched individuals who received a booster mRNA vaccine and controls of the same sex, age group, postal code, type of vaccine, time since primary vaccination, and number of previous tests. We estimated risk of laboratory-confirmed SARS-CoV-2 infection using the Kaplan-Meier method and compared groups using risk ratios (RR) and risk differences. Vaccine effectiveness was calculated as one minus RR.

Findings: Between Jan 3, and Feb 6, 2022, 3 111 159 matched pairs were included in our study. Overall, the estimated effectiveness from day 7 to 34 after a booster was 51·3% (95% CI 50·2-52·4). Estimated effectiveness was 52·5% (51·3-53·7) for an mRNA-1273 booster and 46·2% (43·5-48·7) for a BNT162b2 booster. Effectiveness was 58·6% (55·5-61·6) if primary vaccination had been with ChAdOx1 nCoV-19 (Oxford-AstraZeneca), 55·3% (52·3-58·2) with mRNA-1273 (Moderna), 49·7% (48·3-51·1) with BNT162b2 (Pfizer-BioNTech), and 48·0% (42·5-53·7) with Ad26.COV2.S (Janssen). Estimated effectiveness was 43·6% (40·0-47·1) when the booster was administered between 151 days and 180 days after complete vaccination and 52·2% (51·0-53·3) if administered more than 180 days after primary scheduled completion.

Interpretation: Booster mRNA vaccine-doses were moderately effective in preventing infection with the omicron variant of SARS-CoV-2 for over a month after administration, which indicates their suitability as a strategy to limit the health effects of COVID-19 in periods of omicron variant domination. Estimated effectiveness was higher for mRNA-1273 compared with BNT162b2 and increased with time between completed primary vaccination and booster.

Funding: None.

Citing Articles

Impact of Repeated Variant Exposures on Cellular and Humoral Immunogenicity Induced by SARS-CoV-2 Vaccines.

Fernandez-Ciriza L, Del Pozo J, Betanzos N, Gonzalez A, Fernandez-Montero A, Carmona-Torre F Vaccines (Basel). 2025; 12(12.

PMID: 39772069 PMC: 11680034. DOI: 10.3390/vaccines12121408.

COVID-19 Vaccine Effectiveness of Booster Doses Against Delta and Omicron Variants Over Follow-up Times Using Longitudinal Meta-analysis.

Mostafavi F, Bahardoust M, Sera F, Amirabadizadeh A, Allahyari S, Ssentongod P J Res Health Sci. 2024; 24(4):e00626.

PMID: 39431651 PMC: 11492529. DOI: 10.34172/jrhs.2024.161.

Vaccination against rapidly evolving pathogens and the entanglements of memory.

Cobey S Nat Immunol. 2024; 25(11):2015-2023.

PMID: 39384979 DOI: 10.1038/s41590-024-01970-2.

Effectiveness of the First and Second Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Dose: A Nationwide Cohort Study From Austria on Hybrid Versus Natural Immunity.

Chalupka A, Riedmann U, Richter L, Chakeri A, El-Khatib Z, Sprenger M Open Forum Infect Dis. 2024; 11(10):ofae547.

PMID: 39371370 PMC: 11450622. DOI: 10.1093/ofid/ofae547.

Effectiveness of the fourth dose of COVID-19 vaccines against severe COVID-19 among adults 40 years or older in Brazil: a population-based cohort study.

Lazar Neto F, Hitchings M, Amin A, de Franca G, Lind M, Scaramuzzini Torres M Lancet Reg Health Am. 2024; 34:100755.

PMID: 38737773 PMC: 11087726. DOI: 10.1016/j.lana.2024.100755.

References

Collie S, Champion J, Moultrie H, Bekker L, Gray G . Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa. N Engl J Med. 2021; 386(5):494-496. PMC: 8757569. DOI: 10.1056/NEJMc2119270. View

Planas D, Saunders N, Maes P, Guivel-Benhassine F, Planchais C, Buchrieser J . Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. 2022; 602(7898):671-675. DOI: 10.1038/s41586-021-04389-z. View

Israel A, Merzon E, Schaffer A, Shenhar Y, Green I, Golan-Cohen A . Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection: test negative design study. BMJ. 2021; 375:e067873. PMC: 9083235. DOI: 10.1136/bmj-2021-067873. View

Atmar R, Lyke K, Deming M, Jackson L, Branche A, El Sahly H . Homologous and Heterologous Covid-19 Booster Vaccinations. N Engl J Med. 2022; 386(11):1046-1057. PMC: 8820244. DOI: 10.1056/NEJMoa2116414. View

Thomas S, Moreira Jr E, Kitchin N, Absalon J, Gurtman A, Lockhart S . Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N Engl J Med. 2021; 385(19):1761-1773. PMC: 8461570. DOI: 10.1056/NEJMoa2110345. View

Choi A, Koch M, Wu K, Chu L, Ma L, Hill A . Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis. Nat Med. 2021; 27(11):2025-2031. PMC: 8604720. DOI: 10.1038/s41591-021-01527-y. View

Abu-Raddad L, Chemaitelly H, Ayoub H, Almukdad S, Yassine H, Al-Khatib H . Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar. N Engl J Med. 2022; 386(19):1804-1816. PMC: 8929389. DOI: 10.1056/NEJMoa2200797. View

Buchan S, Chung H, Brown K, Austin P, Fell D, Gubbay J . Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe Outcomes. JAMA Netw Open. 2022; 5(9):e2232760. PMC: 9500552. DOI: 10.1001/jamanetworkopen.2022.32760. View

Andrews N, Stowe J, Kirsebom F, Toffa S, Sachdeva R, Gower C . Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England. Nat Med. 2022; 28(4):831-837. PMC: 9018410. DOI: 10.1038/s41591-022-01699-1. View

10.

Munro A, Janani L, Cornelius V, Aley P, Babbage G, Baxter D . Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021; 398(10318):2258-2276. PMC: 8639161. DOI: 10.1016/S0140-6736(21)02717-3. View

11.

Gruell H, Vanshylla K, Tober-Lau P, Hillus D, Schommers P, Lehmann C . mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. Nat Med. 2022; 28(3):477-480. PMC: 8767537. DOI: 10.1038/s41591-021-01676-0. View

12.

Thompson M, Natarajan K, Irving S, Rowley E, Griggs E, Gaglani M . Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August.... MMWR Morb Mortal Wkly Rep. 2022; 71(4):139-145. PMC: 9351525. DOI: 10.15585/mmwr.mm7104e3. View

13.

Tseng H, Ackerson B, Luo Y, Sy L, Talarico C, Tian Y . Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. Nat Med. 2022; 28(5):1063-1071. PMC: 9117141. DOI: 10.1038/s41591-022-01753-y. View

14.

Tartof S, Slezak J, Fischer H, Hong V, Ackerson B, Ranasinghe O . Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021; 398(10309):1407-1416. PMC: 8489881. DOI: 10.1016/S0140-6736(21)02183-8. View

15.

Accorsi E, Britton A, Fleming-Dutra K, Smith Z, Shang N, Derado G . Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. JAMA. 2022; 327(7):639-651. PMC: 8848203. DOI: 10.1001/jama.2022.0470. View

16.

Ferdinands J, Rao S, Dixon B, Mitchell P, DeSilva M, Irving S . Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10.... MMWR Morb Mortal Wkly Rep. 2022; 71(7):255-263. PMC: 8853475. DOI: 10.15585/mmwr.mm7107e2. View

17.

Barda N, Dagan N, Cohen C, Hernan M, Lipsitch M, Kohane I . Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet. 2021; 398(10316):2093-2100. PMC: 8555967. DOI: 10.1016/S0140-6736(21)02249-2. View

18.

Sheikh A, Kerr S, Woolhouse M, McMenamin J, Robertson C . Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design. Lancet Infect Dis. 2022; 22(7):959-966. PMC: 9033213. DOI: 10.1016/S1473-3099(22)00141-4. View

19.

Wu M, Wall E, Carr E, Harvey R, Townsley H, Mears H . Three-dose vaccination elicits neutralising antibodies against omicron. Lancet. 2022; 399(10326):715-717. PMC: 8769665. DOI: 10.1016/S0140-6736(22)00092-7. View

20.

Bar-On Y, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Kalkstein N . Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel. N Engl J Med. 2021; 385(15):1393-1400. PMC: 8461568. DOI: 10.1056/NEJMoa2114255. View